Datavault AI Inc. (NASDAQ: DVLT), a technology company focused on AI-driven data monetization and digital asset infrastructure, has entered the pharmaceutical landscape through an exclusive licensing agreement with Wellgistics Health Inc. The agreement, announced today, grants Wellgistics Health sole access within its market segment to Datavault AI's proprietary technologies, positioning them at the center of a platform designed to streamline prescription distribution and reduce reliance on traditional intermediaries.
At the heart of the initiative is PharmacyChain™, a platform designed to track and manage prescription fulfillment from manufacturer to patient while automating processes that are traditionally routed through pharmacy benefit managers (PBMs). PBMs are intermediaries that manage prescription drug benefits for health insurers, and their complex rebate structures have been widely criticized for contributing to high drug prices. Prescription drug prices in the United States are among the highest in the world, driven in part by these opaque systems.
By granting an exclusive license, Datavault AI creates a stronger commercial incentive for adoption while also reinforcing the value of its intellectual property portfolio. The exclusivity is a defining feature of the agreement, as it prevents direct competitors from using the same technology within Wellgistics Health's market segment.
This move comes amid growing scrutiny of PBM practices and their impact on healthcare costs. The PharmacyChain platform aims to increase transparency and efficiency in the prescription supply chain, potentially leading to lower costs for patients and providers. For Datavault AI, the partnership represents an expansion into the healthcare sector, leveraging its existing AI and data monetization expertise in a new vertical.
The latest news and updates relating to DVLT are available in the company’s newsroom at https://ibn.fm/DVLT.
